CorMedix Inc. (CRMD) company profile
Close on Nov 17, 2026Market cap $364.00MP/E –Yield –
About CorMedix
Pharmaceutical Preparations, SIC 2834
CorMedix Inc. is a biopharmaceutical company that develops and commercializes therapeutic products for life-threatening conditions. Its primary commercial product is DefenCath, an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult hemodialysis patients using central venous catheters. Through its Melinta Therapeutics subsidiary, the company also markets infectious disease and cardiovascular medications, including REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA, and TOPROL-XL. CorMedix provides these treatments to healthcare providers across various clinical settings, including inpatient hospitals, outpatient dialysis centers, emergency departments, outpatient clinics, and home infusion care facilities.
The company conducts its commercial operations in the United States, where its contracted customer base spans approximately 60% of outpatient dialysis facilities through agreements with large and mid-sized dialysis organizations. CorMedix is headquartered in Parsippany, New Jersey.
Summary of the business section of CorMedix's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CorMedix Inc.
- Headquarters
- Parsippany, NJ
- Address
- 389 Interpace Pkwy, Suite 450 07054
- Phone
- (908) 517-9500
- Website
- cormedix.com
- Employees
- 191, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C, Morristown, New Jersey
Stock & identifiers
- Ticker
- CRMD
- Exchange
- Nasdaq
- IPO date
- Mar 26, 2010
- Shares outstanding
- 78M, Aug 10, 2026
- Public float
- $909.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-5 reverse, Mar 26, 2019
- SEC CIK
- 1410098
- CUSIP
- 21900C308
- ISIN
- US21900C3088
- FIGI
- BBG000Q4BQK0
- Share class FIGI
- BBG001T6FWS5
- LEI
- 5299006YIA3L0MBW8358
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joseph Todisco | Chief Executive Officer, Director | 854,749 |
| Kaufman Beth Zelnick | Chief Legal Officer | 260,684 |
| Elizabeth Hurlburt | Chief Operating Officer | 270,463 |
| Susan Blum | Chief Financial Officer | 124,315 |
| Michael David Seckler | Chief Commercial Officer | 133,156 |
| Matthew T. David | Chief Financial Officer | 95,270 |
| Erin Mistry | EVP, Chief Commercial Officer | 100,992 |
| Janet Dillione | Director | 117,835 |
| Robert A. Stewart | Director | 66,453 |
| Myron Kaplan | Director | 261,487 |
| Gregory Scott Duncan | Director | 68,786 |
| Steven W. Lefkowitz | Director | 158,103 |
| Alan W. Dunton | Director | 70,703 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $6.10M | $8.87M | $3.75M | $276 | – |
| FY2024 | $2.36M | $5.39M | $1.11M | $192 | – |
| FY2023 | $2.46M | $1.87M | $1.18M | $89 | – |
| FY2022 David | $1.14M | $798.47K | $933.72K | $93 | – |
| FY2022 Todisco | $2.69M | $3.21M | $933.72K | $93 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Joseph Todisco Chief Executive Officer | $684.35K | $4.49M | $865.07K | $59.25K | $6.10M | +159% |
| Elizabeth Hurlburt Executive Vice President, Chief Operating Officer (3) | $479.64K | $2.78M | $420.53K | $59.20K | $3.74M | +230% |
| Beth Zelnick Kaufman Executive Vice President, Chief Legal/Compliance Officer & Corp. Secretary | $497.60K | $2.78M | $435.94K | $48.06K | $3.77M | +427% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 26, 2010
- Offer price
- $6.50
- Securities offered
- 1,925,000
- Gross proceeds
- $12.51M
- Exchange
- NYSE
- First trading day
- May 13, 2010
- First-day close
- $3.00-53.8%
- Lock-up ends (est.)
- Nov 9, 2010
“Per Unit Total Public offering price $ 6.50 $ 12,512,500 Underwriting discount and commissions (1) $ 0.5525 $ 1,063,562.50 Proceeds to us, before expenses $ 5.9475 $ 11,448,937.50 (1) Does not include a corporate finance fee in the amount of 2% of the gross proceeds of the offering, excluding any over-allotment pr”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 28, 2026 we employed approximately 191 full-time employees,”
Corporate history
Events identified from SEC filings
See a number that looks wrong?